Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence
Pharmaceutics · 02.11.2026 · 18 (11) · 1410
DOI: 10.3390/pharmaceutics18111410 ↗Kurz gefasst
Scoping Review in der Zeitschrift Pharmaceutics, online erschienen am 02.11.2026. Verfasst von Vanessa Bolchis und 11 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “VICTOR BABES” UNIVERSITY OF MEDICINE AND PHARMACY, TIMISOARA, ROMANIA.
Abstract (Originalsprache)
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, yet their periodontal, peri-implant, salivary, and oral microbial effects remain incompletely characterized. This scoping review mapped the clinical and preclinical evidence on GLP-1RA-related oral effects, investigated mechanisms, and knowledge gaps.
Methods
PubMed, Scopus, and the Web of Science Core Collection were searched from inception to 9 September 2026. Original human, animal in vivo, in vitro/ex vivo, and mixed-design studies were eligible when a GLP-1RA was a principal intervention or exposure and a relevant oral or orofacial outcome was reported. Two reviewers independently screened records. Study characteristics, interventions, outcomes, and findings were charted and synthesized descriptively. The review followed Joanna Briggs Institute methodology and PRISMA-ScR guidance and was registered on the Open Science Framework after study selection but before completion of the methodological appraisal and manuscript.
Results
Twenty-seven publications were included, 23 of which were wholly or partly preclinical. Four publications were exclusively human, and one mixed-design publication included an additional human observational component. Experimental findings suggested anti-inflammatory, antioxidant, and osteogenic effects, but molecular responses were not consistently accompanied by structural benefits. Evidence concerning salivary function, oral microbial changes, and orofacial adverse events was limited and heterogeneous. Human findings were derived from non-randomized observational and descriptive designs.
Conclusions
Evidence of potential oral effects is predominantly experimental, and human data are insufficient to establish clinical benefit or causality. Prospective controlled studies with standardized clinical outcomes are needed to determine whether experimental findings translate into meaningful oral-health benefits.
Förderung
- “VICTOR BABES” UNIVERSITY OF MEDICINE AND PHARMACY, TIMISOARA, ROMANIA
Zitieren
APA
Bolchis, V., Fratila, A. D., Dumitrescu, R., Popescu, S., Pirvu, O., Galuscan, A., Balean, O., Floare, L., Jumanca, D., Alexa, V. T., Abrudan-Luca, D., & Chioran, D. (2026). Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence. Pharmaceutics, 18(11), 1410. https://doi.org/10.3390/pharmaceutics18111410
Vancouver
Bolchis V, Fratila AD, Dumitrescu R, Popescu S, Pirvu O, Galuscan A, et al. Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence. Pharmaceutics. 2026;18(11):1410. doi:10.3390/pharmaceutics18111410
BibTeX
@article{Bolchis2026,
author = {Bolchis, Vanessa and Fratila, Aurora Doris and Dumitrescu, Ramona and Popescu, Simona and Pirvu, Oana and Galuscan, Atena and Balean, Octavia and Floare, Lucian and Jumanca, Daniela and Alexa, Vlad Tiberiu and Abrudan-Luca, Delia and Chioran, Doina},
title = {Beyond Glycemic Control: Periodontal, Salivary, and Oral Microbiome Effects of GLP-1 Receptor Agonists—A Scoping Review of Clinical and Preclinical Evidence},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1410},
doi = {10.3390/pharmaceutics18111410}
}
EUVIMED